CytRx soft tissue sarcomas drug gets FDA ODD
Following the completion of an ongoing open-label Phase 1b clinical trial, the company intends to start INNO-206 Phase 2b trial with late-stage soft tissue sarcomas in the second
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.